Journal of Clinical and Aesthetic Dermatology

MAY 2018

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: https://jcadonline.epubxp.com/i/979610

Contents of this Issue

Navigation

Page 36 of 55

37 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY May 2018 • Volume 11 • Number 5 O R I G I N A L R E S E A R C H ACKNOWLEDGMENTS The authors thank Clinton Bertram, PhD, an employee of Eli Lilly and Company, for writing and editorial support. REFERENCES 1. Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb). 2016;6(1): 1–12. doi:10.1007/s13555-015-0092-3. 2. Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50. doi:10.2147/JIR.S100940. 3. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate- to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56. doi:10.1056/ NEJMoa1512711. 4. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-51. doi:10.1016/S0140– 6736(15)60125-8. JCAD TABLE 2. Summary of treatment emergent adverse events DOSING PERIOD DOSING REGIMEN PATIENTS WITH ≥1 TEAE, n (%) TEAE SEVERIT Y MILD MODERATE SEVERE INDUCTION DOSING PERIOD (WEEKS 0–12) IXE Q2W a (N=6) 5 (83.3) 2 (33.3) 2 (33.3) 1 (16.7) IXE Q4W a (N=6) 5 (83.3) 3 (50.0) 2 (33.3) 0 MAINTENANCE DOSING PERIOD (WEEKS 12–48) IXE Q2W/Q4W a (N=6) 3 (50.0) 2 (33.3) 1 (16.7) 0 IXE Q4W/Q4W a (N=6) 6 (100.0) 3 (50.0) 3(50.0) 0 n=number; IXE=ixekizumab; Q2W=every 2 weeks; Q4W=every 4 weeks; TEAE=treatment-emergent adverse event aPatients were randomized to receive 80 mg ixekizumab either every 2 or every 4 weeks during induction (weeks 0-12) following an initial dose of 160 mg ixekizumab. After week 12, all patients received 80 mg ixekizumab every 4 weeks.

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MAY 2018